Hutchinson J H, Charleson S, Evans J F, Falgueyret J P, Hoogsteen K, Jones T R, Kargman S, Macdonald D, McFarlane C S, Nicholson D W
Department of Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, Pointe-Claire, Dorval, Quebec, Canada.
J Med Chem. 1995 Oct 27;38(22):4538-47. doi: 10.1021/jm00022a020.
The attachment of an arylacetic or benzoic acid moiety to the thiopyrano[2,3,4-c,d]indole nucleus results in compounds which are highly potent and selective 5-lipoxygenase (5-LO) inhibitors. These compounds are structurally simpler than previous compounds of similar potency in that they contain a single chiral center. From the data presented, 2-[[1-(3-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]- 4, 5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]methoxy]-phenylacetic acid, 14b, was shown to inhibit 5-hydroperoxyeicosatetraenoic acid (5-HPETE) production by human 5-LO (IC50 of 18 nM). The acid 14b is highly selective as an inhibitor of 5-LO activity when compared to the inhibition of ram seminal vesicle cyclooxygenase (IC50 > 5 microM) or human leukocyte leukotriene A4 (LTA4) hydrolase (IC50 > 20 microM). In addition, 14b was inactive in a 5-lipoxygenase-activating protein (FLAP) binding assay at 10 microM. In vivo studies showed that 14b is bioavailable in rat and functionally active in the hyperreactive rat model of antigen-induced dyspnea (74% inhibition at 0.5 mk/kg po; 2 h pretreatment). In the conscious squirrel monkey model of asthma, 14b showed excellent functional activity at 0.1 mg/kg against antigen-induced bronchoconstriction (94% inhibition of the increase in RL and 100% inhibition in the decrease in Cdyn; n = 4). Resolution of this compound gave (-)-14b, the most potent enantiomer (IC50 = 10 nM in the human 5-LO assay), which was shown to possess the S configuration at the chiral center by X-ray crystallographic analysis of an intermediate. Subsequent studies on the aryl thiopyrano[2,3,4-c,d]indole series of inhibitors led to the discovery of potent dual inhibitors of both FLAP and 5-LO, the most potent of which is 2-[[1-(4-chlorobenzyl)-4-methyl-6-(quinolin-2-ylmethoxy)-4, 5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]methoxy]phenylacetic acid, 19. Acid 19 has an IC50 of 100 nM for the inhibition of 5-HPETE production by human 5-LO and is active in a FLAP binding assay with an IC50 of 32 nM. Furthermore, thiopyrano[2,3,4-c,d]indoles such as 1 and 14b are capable of inhibiting the LTC4 synthase reaction in a dose dependent manner (IC50s of 11 and 16 microM, respectively, compared to that of LTC2 at 1.2 microM) in contrast to other, structurally distinct 5-LO inhibitors. It has also been observed that the thiopyrano[2,3,4-c,d]indole class of compounds strongly promotes the translocation of 5-LO from the cytosol to a membrane fraction in the presence or absence of the ionophore A23187.(ABSTRACT TRUNCATED AT 400 WORDS)
将芳基乙酸或苯甲酸部分连接到硫代吡喃并[2,3,4 - c,d]吲哚核上可得到具有高效力和选择性的5 - 脂氧合酶(5 - LO)抑制剂的化合物。这些化合物在结构上比之前具有相似效力的化合物更简单,因为它们只含有一个手性中心。根据所提供的数据,2 - [[1 - (3 - 氯苄基)-4 - 甲基 - 6 - [(5 - 苯基吡啶 - 2 - 基)甲氧基]-4,5 - 二氢 - 1H - 硫代吡喃并[2,3,4 - c,d]吲哚 - 2 - 基]甲氧基] - 苯乙酸(14b)被证明可抑制人5 - LO产生5 - 氢过氧化二十碳四烯酸(5 - HPETE)(IC50为18 nM)。与抑制兔精囊环氧化酶(IC50 > 5 μM)或人白细胞白三烯A4(LTA4)水解酶(IC50 > 20 μM)相比,酸14b作为5 - LO活性抑制剂具有高度选择性。此外,在10 μM浓度下,14b在5 - 脂氧合酶激活蛋白(FLAP)结合试验中无活性。体内研究表明,14b在大鼠体内具有生物利用度,并且在抗原诱导的呼吸困难的高反应性大鼠模型中具有功能活性(口服0.5 mg/kg;预处理2小时后抑制率为74%)。在清醒的松鼠猴哮喘模型中,14b在0.1 mg/kg剂量下对抗抗原诱导的支气管收缩表现出优异的功能活性(对RL增加的抑制率为94%,对Cdyn降低的抑制率为100%;n = 4)。该化合物拆分后得到( - )-14b,其为效力最强的对映体(在人5 - LO试验中的IC50 = 10 nM),通过对一种中间体的X射线晶体学分析表明其在手性中心处具有S构型。随后对芳基硫代吡喃并[2,3,4 - c,d]吲哚系列抑制剂的研究导致发现了FLAP和5 - LO的强效双重抑制剂,其中效力最强的是2 - [[1 - (4 - 氯苄基)-4 - 甲基 - 6 - (喹啉 - 2 - 基甲氧基)-4,5 - 二氢 - 1H - 硫代吡喃并[2,3,4 - c,d]吲哚 - 2 - 基]甲氧基]苯乙酸(19)。酸19抑制人5 - LO产生5 - HPETE的IC50为100 nM,并且在FLAP结合试验中具有活性,IC50为32 nM。此外,与其他结构不同的5 - LO抑制剂相比,硫代吡喃并[2,3,4 - c,d]吲哚如1和14b能够以剂量依赖的方式抑制LTC4合酶反应(IC50分别为11和16 μM,而LTC2为1.2 μM)。还观察到,在存在或不存在离子载体A23187的情况下,硫代吡喃并[2,3,4 - c,d]吲哚类化合物强烈促进5 - LO从胞质溶胶向膜部分的转位。(摘要截断于400字)